O le a le uiga o le “manino”?
E le tauaveina e le manu le suiga. O le a le tupu ai le ma'i ma o le a lē tuʻuina atu.
Maile Alaskan Malamute Polyneuropathy (AMPN)
Alaskan Malamute Polyneuropathy (AMPN) is a genetic disorder that affects the nervous system of Alaskan Malamutes. A DNA test for AMPN can help dog owners identify whether their pets are carriers of this condition, which may lead to debilitating symptoms such as muscle weakness and impaired coordination. Early detection through DNA testing is crucial for managing the health of affected dogs, allowing for better care and informed breeding decisions. By knowing your dog's genetic status, you can take proactive steps to ensure a healthier life for your Alaskan Malamute. Don't wait—consider a DNA test today to safeguard your furry friend against AMPN. Protect your dog's well-being with this simple yet essential genetic screening.
Faapuupuuga: AMPN
Su'ega su'esu'e: NDRG1 c.293G>T
Tofi: Autosomal Recessive
Acronym
AMPN
Mata'ituina taimi
Fa'alema'i ogaoga
Fa'avasegaga fa'apitoa
Fa'ama'i Neurological
Iloiloga suiga
NDRG1 c.293G>T
p.(G98V)
p.(G98V)
Faiga o tofi
Autosomal Recessive
Aotelega o su'ega:
Alaskan Malamute Polyneuropathy (AMPN) is a genetic condition affecting the nervous system of Alaskan Malamutes. DNA testing for AMPN helps identify carriers and affected dogs, allowing breeders to make informed decisions to reduce the prevalence of this disorder. Symptoms may include muscle weakness and coordination issues, impacting the dog's quality of life. Early detection through genetic testing can aid in managing the condition effectively. Responsible breeding practices can help ensure healthier future generations of this beloved breed.
E maua mai le pusa: Basic
O lenei su'ega DNA e aofia ai e amata mai i le matou pusa Basic — ma o se vaega foi o pusa Basic, Standard, Advanced, Complete.
Va'ai DNA Su'ega Packs →Filifili le pusa e sili ona fetaui ma lau faʻatupuina poʻo le soifua maloloina o au manu.
Understanding Alaskan Malamute Polyneuropathy (AMPN)
Alaskan Malamute Polyneuropathy (AMPN) is a hereditary neurological disorder that primarily affects Alaskan Malamutes, leading to a range of debilitating symptoms. This condition is characterized by the degeneration of peripheral nerves, which can result in significant mobility issues and impairments in the dog's overall quality of life.
Symptoms of AMPN
Dogs affected by AMPN may exhibit a variety of symptoms, which can vary in severity. Common signs include muscle weakness, difficulty in walking or running, and a noticeable decrease in coordination. As the disease progresses, affected dogs may develop tremors, a wobbly gait, and muscle atrophy. These symptoms often manifest between the ages of 6 months and 2 years, although the onset can vary.
Genetic Basis of AMPN
The condition is caused by a genetic mutation that affects the structure and function of nerve fibers. This mutation can be identified through a DNA test, which helps in diagnosing the condition before clinical signs become apparent. Understanding the genetic basis of AMPN is crucial for breeders and pet owners, as it aids in making informed decisions regarding breeding practices and the management of affected dogs.
Taua ole Su'ega DNA
DNA testing for AMPN plays a vital role in the early detection and management of the disease. By identifying carriers of the genetic mutation, breeders can take steps to avoid mating affected dogs, thereby reducing the incidence of the disorder in future generations. Moreover, knowing a dog’s genetic status can assist owners in making informed decisions about their pet’s care and potential lifestyle adjustments.
Managing AMPN
While there is currently no cure for AMPN, management strategies can significantly improve the quality of life for affected dogs. These may include physical therapy, pain management, and modifications to the dog's environment to accommodate mobility challenges. Regular veterinary check-ups are essential to monitor the condition and adjust treatment plans as needed.
Fa'ai'uga
Alaskan Malamute Polyneuropathy is a serious genetic condition that can severely impact the health and well-being of affected dogs. Through DNA testing, owners and breeders can take proactive steps in managing this disorder, ensuring that future generations of Alaskan Malamutes are healthier and less prone to AMPN. Understanding the implications of this condition is crucial for responsible breeding and compassionate care of affected dogs.
Fa'ailoga ua iloa mo le su'ega: Alaskan Malamute Polyneuropathy (AMPN)
- Alaskan Malamute
🧬 Interpretation of genotypes AMPN
Genotype
Tulaga
🟡 N/N
E le fa'asalalau - Leai se lamatiaga
🟡 N/AMPN
Avetaavale - Leai se lamatiaga
❌ AMPN/AMPN
A'afia - I Tulaga lamatia
FAQ: malamalama i le fa'amatalaga
E mata'utia ea se “Vaveina”?
Leai. E masani ona soifua maloloina le manu ae e mafai ona tuʻuina atu le suiga i lona fanau.
Ae faapefea pe a “Aafia” se manu?
E lua kopi suia. Fa'ailoga fa'afoma'i e fa'amoemoe e fa'atatau i le faama'i. E le tatau ona fafaga.
Aisea e iai le eseesega i le va o tane / fafine?
O nisi faʻamaʻi e fesoʻotaʻi feusuaʻiga, o lea e eseese ai o latou faʻaaliga e faʻatatau i le itupa a manu.
Va'ai le Fanau
N/N (le-faasalalau)
N/AMPN (Va'ava'a)
AMPN/AMPN (A’afia)
Su'ega DNA FAQ
O le a le mea e iloa e lenei su'ega DNA?
This DNA test detects the mutation associated with Alaskan Malamute Polyneuropathy (AMPN) in order to identify clear, carrier, or at-risk animals.
Aisea e su'e ai se manu faifa'ato'aga?
O le su'ega DNA e fesoasoani i le au faifa'ato'aga e fuafua ni faigauo saogalemu ma fa'aitiitia ai le lamatiaga o le tu'uina atu o le suiga i fanau.
O le a le tulaga tofi o lenei suega?
Ole fa'asologa ole tofi na lipotia mo lenei su'ega ole Autosomal Recessive.
O le fea suiga o lo'o su'esu'eina i lenei su'ega?
This test analyses the mutation NDRG1 c.293G>T.
E a'afia se manu fe'avea'i?
E le faapea. O le fa'auigaina e fa'alagolago i le fa'asologa o tofi ma le fa'atupuina o le genotype.
Fa'asinomaga
Bruun Camilla S, Jäderlund Karin H, Berendt Mette, Jensen Kristine B, Spodsberg Eva H, Gredal Hanne, Shelton G Diane, Mickelson James R, Minor Katie M, Lohi Hannes, Bjerkås Inge, Stigen Oyvind, Espenes Arild, Rohdin Cecilia, Edlund Rebecca, Ohlsson Jennie, Cizinauskas Sigitas, Leifsson Páll S, Drögemüller Cord, Moe Lars, Cirera Susanna, Fredholm Merete. A Gly98Val mutation in the N-Myc downstream regulated gene 1 (NDRG1) in Alaskan Malamutes with polyneuropathy. PLoS One. 2013;8(2):e54547. doi: 10.1371/journal.pone.0054547. Epub 2013 Feb 5.